TY - JOUR
T1 - Use of proton pump inhibitors during pregnancy and rates of major malformations
T2 - A meta-analysis
AU - Nikfar, Shekoufeh
AU - Abdollahi, Mohammad
AU - Moretti, Myla E.
AU - Magee, Laura A.
AU - Koren, Gideon
N1 - Funding Information:
Supported by a grant from CIHR and AstraZeneca Ltd, Sweden; Gideon Koren is a Senior Scientist of CIHR and holder of the Research Leadership in Better Pharmacotherapy During Pregnancy and Lactation.
PY - 2002
Y1 - 2002
N2 - Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy. The aim of this study was to systematically analyze the available data on the risk for malformations following use of these agents in the first trimester of pregnancy. Medline, EMBASE, published abstracts, and reference lists were searched for articles reporting on proton pump inhibitor use in pregnancy. Summary relative risks and 95% confidence intervals (95% CI) were calculated using the Mantel-Haenszel method. Five cohort studies met the inclusion criteria for this meta-analysis. With almost 600 exposed pregnancies, the overall relative risk was 1.18 with a 95%CI of 0.72-1.94. In conclusion, proton pump inhibitors do not present a major teratogenic risk when used in recommend doses. These data are reassuring for the countless patients who have used these agents in the early part of their pregnancies.
AB - Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy. The aim of this study was to systematically analyze the available data on the risk for malformations following use of these agents in the first trimester of pregnancy. Medline, EMBASE, published abstracts, and reference lists were searched for articles reporting on proton pump inhibitor use in pregnancy. Summary relative risks and 95% confidence intervals (95% CI) were calculated using the Mantel-Haenszel method. Five cohort studies met the inclusion criteria for this meta-analysis. With almost 600 exposed pregnancies, the overall relative risk was 1.18 with a 95%CI of 0.72-1.94. In conclusion, proton pump inhibitors do not present a major teratogenic risk when used in recommend doses. These data are reassuring for the countless patients who have used these agents in the early part of their pregnancies.
KW - Antiulcer agents
KW - Drug-induced malformations
KW - Omeprazole
KW - Pregnancy
KW - Proton pump inhibitors
UR - https://www.scopus.com/pages/publications/0036311007
U2 - 10.1023/A:1015863018105
DO - 10.1023/A:1015863018105
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12141812
AN - SCOPUS:0036311007
SN - 0163-2116
VL - 47
SP - 1526
EP - 1529
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 7
ER -